Tim Pearson, Elaine Sullivan. (LinkedIn, Carrick)

Tesaro vet jumps to an Irish on­col­o­gy up­start and shifts fo­cus to the US, eye­ing fundrais­ing

Tim Pear­son’s biotech break is over.

Af­ter pick­ing up a $12 mil­lion pay­out late last year fol­low­ing the sale of Tesaro to GSK, the for­mer Tesaro CFO’s next chap­ter in biotech will be writ­ten at an­oth­er can­cer com­pa­ny. 

Pear­son has been named CEO at Car­rick Ther­a­peu­tics, which picked up a $95 mil­lion round three years ago to bring in on­col­o­gy drugs and grow a pipeline. Just 8 months ago the long­time deal­mak­er George Golumbes­ki joined the Dublin-based com­pa­ny — with op­er­a­tions in the UK as well — as chair­man of the board. And now Golumbes­ki is in­stalling Pear­son as chief ex­ec­u­tive while com­pa­ny founder Elaine Sul­li­van tran­si­tions to a sup­port role as ad­vis­er and “ex­ec­u­tive en­tre­pre­neur.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.